Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O15066
UPID:
KIF3B_HUMAN
Alternative names:
HH0048; Microtubule plus end-directed kinesin motor 3B
Alternative UPACC:
O15066; B2RMP4; B4DSR5; E1P5M5
Background:
Kinesin-like protein KIF3B, also known as HH0048 and Microtubule plus end-directed kinesin motor 3B, is a microtubule-based molecular motor. It plays a crucial role in transporting intracellular cargos, such as vesicles, organelles, and protein complexes, by utilizing ATP hydrolysis. KIF3B is instrumental in cilia formation and maintaining photoreceptor integrity, specifically in rod photoreceptors, and facilitates the trafficking of vesicles containing NMDA receptor subunit GRIN2A into neuronal dendrites.
Therapeutic significance:
Given its involvement in Retinitis pigmentosa 89, a retinal dystrophy characterized by night vision blindness and loss of midperipheral visual field, Kinesin-like protein KIF3B presents a promising target for therapeutic intervention. Understanding the role of Kinesin-like protein KIF3B could open doors to potential therapeutic strategies for treating not only retinal dystrophies but also related ciliopathies.